[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.108.121. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
November 1, 2006

Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(17):2087-2089. doi:10.1001/jama.296.17.2088-a

To the Editor: The OASIS-6 trial1 was not the first to demonstrate that a 7-day (or hospitalization duration) treatment with an anticoagulant is superior to a 48-hour infusion of UFH therapy. Both the Assessment of the Safety and Efficacy of New Thrombolytic Regimen 3 (ASSENT-3) trial2 and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Events (ESSENCE) trial3 have shown similar findings. A trial of anticoagulant with an equal duration of UFH did not display this difference.4 The differences in treatment duration in OASIS-6 may have affected the development of deep vein thrombosis (DVT) and pulmonary embolism.

First Page Preview View Large
First page PDF preview
First page PDF preview
×